213 related articles for article (PubMed ID: 7917768)
1. Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
Minton NA
Br J Clin Pharmacol; 1994 Jun; 37(6):525-30. PubMed ID: 7917768
[TBL] [Abstract][Full Text] [Related]
2. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
Cooper M; Sologuren A; Valiente R; Smith J
Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
[TBL] [Abstract][Full Text] [Related]
3. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antiemetic effects of a 5-HT1A agonist, LY228729, and 5-HT3 antagonists in the pigeon.
Wolff MC; Leander JD
Pharmacol Biochem Behav; 1995 Nov; 52(3):571-5. PubMed ID: 8545476
[TBL] [Abstract][Full Text] [Related]
5. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
Gridelli C
Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
[TBL] [Abstract][Full Text] [Related]
6. Ipecacuanha-induced emesis: a human model for testing antiemetic drug activity.
Minton N; Swift R; Lawlor C; Mant T; Henry J
Clin Pharmacol Ther; 1993 Jul; 54(1):53-7. PubMed ID: 8101150
[TBL] [Abstract][Full Text] [Related]
7. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and preclinical antiemetic properties of ondansetron.
Tyers MB
Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
[TBL] [Abstract][Full Text] [Related]
9. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
10. [An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].
Tsukagoshi S; Ohta J; Taguchi T
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2108-14. PubMed ID: 8239673
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin].
Yamada Y; Fujita M; Okuyama K; Takayanagi R; Ozeki T; Yokoyama H; Iga T
Yakugaku Zasshi; 2007 Feb; 127(2):353-7. PubMed ID: 17268155
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antiemetic interactions between serotonergic 5-HT3 and tachykininergic NK1-receptor antagonists in the least shrew (Cryptotis parva).
Darmani NA; Chebolu S; Amos B; Alkam T
Pharmacol Biochem Behav; 2011 Oct; 99(4):573-9. PubMed ID: 21683089
[TBL] [Abstract][Full Text] [Related]
13. [Use of ondansetron, a 5-HT3 receptor antagonist, as a new type of antiemetic in pediatric oncology].
Csáki C; Ferencz T; Koós R; Schuler D; Borsi J
Orv Hetil; 1993 Jun; 134(25):1363-7. PubMed ID: 8332356
[TBL] [Abstract][Full Text] [Related]
14. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
15. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
16. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
17. Broad-spectrum antiemetic potential of the L-type calcium channel antagonist nifedipine and evidence for its additive antiemetic interaction with the 5-HT(3) receptor antagonist palonosetron in the least shrew (Cryptotis parva).
Darmani NA; Zhong W; Chebolu S; Vaezi M; Alkam T
Eur J Pharmacol; 2014 Jan; 722():2-12. PubMed ID: 24513517
[TBL] [Abstract][Full Text] [Related]
18. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
[TBL] [Abstract][Full Text] [Related]
19. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
[TBL] [Abstract][Full Text] [Related]
20. Optimising antiemetic therapy: what are the problems and how can they be overcome?
Aapro M
Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
